Table 3 SIRs of second primary cancers in survivors of multiple myeloma (MM) by age at diagnosis of first MM in Germany and Sweden * .
From: Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries
Sites of second cancers | Germany | Sweden | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
<65 yrs | 65–74 yrs | ≥75 yrs | <65 yrs | 65–74 yrs | ≥75 yrs | |||||||||||||
N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | |
Stomach | 18 | 2.4 | (1.4–3.8) | 11 | 0.8 | (0.4–1.4) | 12 | 0.8 | (0.4–1.4) | 0 | 0.0 | 2 | 2.3 | (0.3–8.4) | 6 | 1.3 | (0.5–2.8) | |
Colorectum | 24 | 0.8 | (0.5–1.2) | 41 | 0.7 | (0.5–1.0) | 39 | 0.7 | (0.5–1.0) | 8 | 1.0 | (0.4–1.9) | 19 | 1.5 | (0.9–2.3) | 30 | 1.3 | (0.9–1.9) |
Liver and gallbladder | 2 | 0.4 | (0.0–1.4) | 13 | 1.3 | (0.7–2.3) | 8 | 0.9 | (0.4–1.8) | 0 | 0.0 | 1 | 1.3 | (0.0–7.2) | 5 | 1.6 | (0.5–3.7) | |
Lung | 23 | 0.8 | (0.5–1.2) | 36 | 0.8 | (0.6–1.1) | 25 | 0.9 | (0.6–1.3) | 10 | 1.4 | (0.7–2.6) | 7 | 1.3 | (0.5–2.7) | 5 | 1.1 | (0.3–2.5) |
Breast | 21 | 0.7 | (0.4–1.1) | 28 | 0.8 | (0.5–1.2) | 20 | 0.7 | (0.4–1.1) | 12 | 0.8 | (0.4–1.5) | 10 | 1.7 | (0.8–3.0) | 8 | 1.3 | (0.6–2.5) |
Endometrium | 4 | 0.8 | (0.2–2.0) | 2 | 0.3 | (0.0–0.9) | 2 | 0.3 | (0.0–1.1) | 4 | 1.5 | (0.4–3.9) | 0 | 0.0 | 1 | 0.6 | (0.0–3.4) | |
Prostate | 26 | 0.6 | (0.4–0.9) | 63 | 0.8 | (0.6–1.1) | 28 | 0.7 | (0.4–1.0) | 17 | 1.1 | (0.6–1.7) | 21 | 1.4 | (0.9–2.2) | 27 | 1.2 | (0.8–1.7) |
Kidney | 18 | 1.9 | (1.1–3.0) | 13 | 1.0 | (0.5–1.6) | 4 | 0.4 | (0.1–1.1) | 4 | 4.2 | (1.1–11) | 6 | 2.1 | (0.8–4.5) | 7 | 2.0 | (0.8–4.1) |
Urinary bladder | 5 | 0.7 | (0.2–1.5) | 8 | 0.5 | (0.2–0.9) | 10 | 0.6 | (0.3–1.1) | 2 | 1.3 | (0.2–4.5) | 9 | 1.4 | (0.6–2.6) | 8 | 0.7 | (0.3–1.4) |
Melanoma | 11 | 1.5 | (0.8–2.7) | 13 | 1.4 | (0.8–2.4) | 7 | 1.0 | (0.4–2.1) | 2 | 0.8 | (0.1–3.0) | 18 | 1.5 | (0.9–2.4) | 2 | 1.3 | (0.2–4.7) |
Nervous system | 6 | 1.9 | (0.7–4.1) | 5 | 1.3 | (0.4–3.0) | 1 | 0.4 | (0.0–2.4) | 5 | 2.0 | (0.6–4.6) | 6 | 1.3 | (0.5–2.8) | 6 | 4.0 | (1.5–8.6) |
Non–Hodgkin lymphoma | 5 | 0.8 | (0.3–1.8) | 11 | 1.1 | (0.5–1.9) | 6 | 0.7 | (0.2–1.4) | 3 | 1.1 | (0.2–3.3) | 4 | 1.3 | (0.4–3.4) | 9 | 1.9 | (0.9–3.6) |
Leukemia | 20 | 4.2 | (2.5–6.4) | 11 | 1.4 | (0.7–2.4) | 4 | 0.6 | (0.2–1.4) | 6 | 1.7 | (0.6–3.8) | 9 | 2.0 | (0.9–3.8) | 9 | 1.3 | (0.6–2.5) |
Myeloid leukemia | 19 | 11 | (6.3–16) | 8 | 2.5 | (1.1–4.9) | 4 | 1.3 | (0.4–3.4) | 3 | 1.3 | (0.3–3.9) | 7 | 2.5 | (1.0–5.2) | 4 | 1.9 | (0.5–4.8) |
Acute myeloid leukemia | 15 | 14 | (8.0–24) | 6 | 3.1 | (1.1–6.8) | 3 | 1.7 | (0.3–4.9) | 3 | 1.5 | (0.3–4.3) | 7 | 2.9 | (1.2–6.0) | 3 | 2.7 | (0.6–7.9) |
Chronic myeloid leukemia | 0 | 0.0 | 1 | 1.2 | (0.0–6.8) | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | ||||||
Unknown primary | 6 | 1.7 | (0.6–3.7) | 4 | 0.6 | (0.2–1.6) | 6 | 0.8 | (0.3–1.8) | 3 | 1.5 | (0.3–4.3) | 0 | 0.0 | 7 | 1.9 | (0.8–3.9) | |
Total combined a | 245 | 1.1 | (1.0–1.2) | 305 | 0.9 | (0.8–1.0) | 202 | 0.7 | (0.6–0.8) | 87 | 1.2 | (1.0–1.5) | 124 | 1.4 | (1.2–1.7) | 138 | 1.2 | (1.0–1.5) |
